Antipsychotics and their Impact on Biopsychosocial Outcomes in Schizophrenia: A Randomized Comparative Study
Indian Journal of Social Psychiatry · 2026-01 · 42 (1) · 33-40
DOI: 10.4103/ijsp.ijsp_371_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Social Psychiatry, online erschienen am 12.03.2026. Verfasst von Shivam Tyagi und 2 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Functional recovery and social integration are central goals in schizophrenia treatment, yet are seldom evaluated alongside symptom remission. Traditional trials prioritize psychosis reduction, overlooking quality-of-life (QoL), social functioning, and sexual health domains critical to personal and social recovery.
Objective
To compare the impact of two antipsychotics on biopsychosocial outcomes i.e., QoL, socio-occupational functioning, and sexual functioning and to assess symptom severity correlations with these biopsychosocial outcomes.
Methods
In this randomized study, 65 adults with schizophrenia received either cariprazine ( n = 33) or risperidone ( n = 32) for 10 weeks. Primary endpoints were change in Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS) scores. The secondary endpoints comprised World Health Organization Quality of Life-Brief scale (WHOQOL-BREF), Social Occupational Functioning Scale (SOFS), and Arizona Sexual Experience Scale (ASEX) scores. Pearson correlations (i.e. ‘r’) assessed associations between symptoms and biopsychosocial outcomes.
Results
At 10 weeks, both groups achieved comparable PANSS-total scores ( P = 0.931). Cariprazine led to significantly lower negative symptoms ( P < 0.001) and higher social relationship domain score, i.e., WHOQOL-D3 ( P = 0.001). BPRS change favored risperidone ( P < 0.001). SOFS and other WHOQOL domains were comparable. ASEX score trends favored cariprazine. Symptom reductions correlated strongly with WHOQOL-general and psychological health domain, i.e., WHOQOL-D2 ( r ≈ −0.9, P < 0.001; for both), moderately with WHOQOL-D3 ( r ≈ −0.5 to − 0.8, P < 0.001) and ASEX ( r ≈ 0.35), and weakly with SOFS ( r ≈ 0.19).
Conclusion
While both antipsychotics yielded comparable symptom control, cariprazine demonstrated superior benefits in negative symptoms and social QoL. Integrating psycho-social and biological measures in therapeutic evaluation emphasizes the importance of functional recovery in schizophrenia care.
Zitieren
APA
Tyagi, S., Sidana, A., & Bhattacharya, S. (2026). Antipsychotics and their Impact on Biopsychosocial Outcomes in Schizophrenia: A Randomized Comparative Study. Indian Journal of Social Psychiatry, 42(1), 33-40. https://doi.org/10.4103/ijsp.ijsp_371_25
Vancouver
Tyagi S, Sidana A, Bhattacharya S. Antipsychotics and their Impact on Biopsychosocial Outcomes in Schizophrenia: A Randomized Comparative Study. Indian Journal of Social Psychiatry. 2026;42(1):33-40. doi:10.4103/ijsp.ijsp_371_25
BibTeX
@article{Tyagi2026,
author = {Tyagi, Shivam and Sidana, Ajeet and Bhattacharya, Sushmita},
title = {Antipsychotics and their Impact on Biopsychosocial Outcomes in Schizophrenia: A Randomized Comparative Study},
journal = {Indian Journal of Social Psychiatry},
year = {2026},
volume = {42},
number = {1},
pages = {33--40},
doi = {10.4103/ijsp.ijsp_371_25}
}
EUVIMED